



dfw
/A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BOSMAN et al.

Atty. Ref.: 2551-149; Confirmation No. 7081

Appl. No. 10/825,219

TC/A.U. 1648

Filed: April 16, 2004

Examiner: Boesen

For: REDOX REVERSIBLE HCV PROTEINS WITH NATIVE-LIKE CONFORMATION

* * * * *

June 11, 2007

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUBMISSION

Submitted herewith is an Information Disclosure Statement with a PTO 1449 Form listing the four references discussed on pages 7-10 of the Amendment filed April 23, 2007. A copy of each of the references is attached. Consideration of the references and return of an initialed copy of the attached PTO 1449 Form as acknowledgement of the same are requested.

BOSMAN et al.
Appl. No. 10/825,219
June 11, 2007
Submission

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
 B. J. Sadoff
 Reg. No. 36,663

BJS:
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Patent Application of

BOSMAN et al.

Serial No. 10/825,219

Filed: April 16, 2004

For: REDOX REVERSIBLE HCV PROTEINS WITH NATIVE-
LIKE CONFORMATION

Atty. Ref.: 2551-149

Group: 1648

Examiner: Boesen

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

June 11, 2007

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☐ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☒ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

06/12/2007 KAHMED1 00000058 10025219
01 FC:1806 180.00 OP

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- ☐ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☒ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☒ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff
Reg. No. 36,663

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100



**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

2551-149

APPLICANT

BOSMAN et al.

FILING DATE

April 16, 2004

SERIAL NO.

10/825,219

GROUP

1648

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Mushiake et al, "Long-term follow up of patients with common variable immunodeficiency treated with intravenous immunoglobulin: Reevaluation of intravenous immunoglobulin replacement therapy", Biotherapy 7:101-107, 1994
	Hofstaetter et al, "S-Sulfonation: a Reversible Chemical Modification of Human Immunoglobulins Permitting Intravenous Application", Vox Sang. 45:155-165 (1983)
	Gronski et al, "S-Sulfonation: a Reversible Chemical Modification of Human Immunoglobulins Permitting Intravenous Application", Vox Sang. 45:144-154 (1983)
	Yamanaka et al, "Clinical Effect and Metabolism of S-Sulfonated Immunoglobulin in 7 Patients with Congenital Humoral Immunodeficiency", Vox Sang. 37:14-20 (1979)

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)